102 related articles for article (PubMed ID: 10535716)
1. Comparison of low-molecular-weight heparin, administered primarily at home, with unfractionated heparin, administered in hospital, and subcutaneous heparin, administered at home for deep-vein thrombosis.
Belcaro G; Nicolaides AN; Cesarone MR; Laurora G; De Sanctis MT; Incandela L; Barsotti A; Corsi M; Vasdekis S; Christopoulos D; Lennox A; Malouf M
Angiology; 1999 Oct; 50(10):781-7. PubMed ID: 10535716
[TBL] [Abstract][Full Text] [Related]
2. Outpatient treatment in patients with acute pulmonary embolism: the Hestia Study.
Zondag W; Mos IC; Creemers-Schild D; Hoogerbrugge AD; Dekkers OM; Dolsma J; Eijsvogel M; Faber LM; Hofstee HM; Hovens MM; Jonkers GJ; van Kralingen KW; Kruip MJ; Vlasveld T; de Vreede MJ; Huisman MV;
J Thromb Haemost; 2011 Aug; 9(8):1500-7. PubMed ID: 21645235
[TBL] [Abstract][Full Text] [Related]
3. Longitudinal evaluation of health plan cost per venous thromboembolism or bleed event in patients with a prior venous thromboembolism event during hospitalization.
Bullano MF; Willey V; Hauch O; Wygant G; Spyropoulos AC; Hoffman L
J Manag Care Pharm; 2005 Oct; 11(8):663-73. PubMed ID: 16194130
[TBL] [Abstract][Full Text] [Related]
4. Six-week low-molecular-weight heparin versus 12-week warfarin for calf deep vein thrombosis: A randomized, prospective, open-label study.
Sartori M; Iotti M; Camporese G; Siragusa S; Imberti D; Bucherini E; Corradini S; Ageno W; Prandoni P; Ghirarduzzi A
Am J Hematol; 2024 May; 99(5):854-861. PubMed ID: 38375893
[TBL] [Abstract][Full Text] [Related]
5. Major bleeding risks of different low-molecular-weight heparin agents: a cohort study in 12 934 patients treated for acute venous thrombosis.
van Rein N; Biedermann JS; van der Meer FJM; Cannegieter SC; Wiersma N; Vermaas HW; Reitsma PH; Kruip MJHA; Lijfering WM
J Thromb Haemost; 2017 Jul; 15(7):1386-1391. PubMed ID: 28440008
[TBL] [Abstract][Full Text] [Related]
6. Step down to 6 months of prophylactic-dose low molecular weight heparin after initial full-dose anticoagulation for the treatment of cancer-associated thrombosis (STEP-CAT): A pilot study.
Popov J; Coelho S; Carrier M; Sperlich C; Solymoss S; Routhier N; Shivakumar S; Aibibula W; Kahn SR; Tagalakis V
J Thromb Haemost; 2022 Aug; 20(8):1868-1874. PubMed ID: 35587536
[TBL] [Abstract][Full Text] [Related]
7. Direct oral anticoagulants decrease treatment failure for acute lower extremity deep venous thrombosis.
Hekman KE; Chao CL; Morgan CE; Helenowski IB; Eskandari MK
Vascular; 2022 Dec; 30(6):1199-1204. PubMed ID: 34569367
[TBL] [Abstract][Full Text] [Related]
8. Effect of anticoagulant treatment on pain in distal deep vein thrombosis: an ancillary analysis from the cactus trial.
Righini M; Robert-Ebadi H; Glauser F; Blondon M; Ouvry P; Diamand JM; Tissot A; Frappe P; Quere I; Kahn SR; Galanaud JP; Le Gal G
J Thromb Haemost; 2019 Mar; 17(3):507-510. PubMed ID: 30656824
[TBL] [Abstract][Full Text] [Related]
9. Management of primary care patients with suspected deep vein thrombosis: use of a therapeutic dose of low-molecular-weight heparin to avoid urgent ultrasonographic evaluation.
Imberti D; Ageno W; Dentali F; Giorgi Pierfranceschi M; Croci E; Garcia D
J Thromb Haemost; 2006 May; 4(5):1037-41. PubMed ID: 16689756
[TBL] [Abstract][Full Text] [Related]
10. Unfractionated Heparin Versus Subcutaneous Nadroparin in Adults Supported With Venovenous Extracorporeal Membrane Oxygenation: a Retrospective, Multicenter Study.
Piwowarczyk P; Borys M; Kutnik P; Szczukocka M; Sysiak-Sławecka J; Szułdrzyński K; Ligowski M; Drobiński D; Czarnik T; Czuczwar M
ASAIO J; 2021 Jan; 67(1):104-111. PubMed ID: 32404610
[TBL] [Abstract][Full Text] [Related]
11. Postoperative nadroparin administration for prophylaxis of thromboembolic events is not associated with an increased risk of hemorrhage after spinal surgery.
Gerlach R; Raabe A; Beck J; Woszczyk A; Seifert V
Eur Spine J; 2004 Feb; 13(1):9-13. PubMed ID: 14615928
[TBL] [Abstract][Full Text] [Related]
12. Low molecular weight heparin once versus twice for thromboprophylaxis following esophagectomy: a randomised, double-blind and placebo-controlled trial.
Song JQ; Xuan LZ; Wu W; Huang JF; Zhong M
J Thorac Dis; 2015 Jul; 7(7):1158-64. PubMed ID: 26380731
[TBL] [Abstract][Full Text] [Related]
13. Prevention of catheter-related venous thrombosis with nadroparin in patients receiving chemotherapy for hematologic malignancies: a randomized, placebo-controlled study.
Niers TM; Di Nisio M; Klerk CP; Baarslag HJ; Büller HR; Biemond BJ
J Thromb Haemost; 2007 Sep; 5(9):1878-82. PubMed ID: 17723127
[TBL] [Abstract][Full Text] [Related]
14. Cost-Effectiveness of Performing Reference Ultrasonography in Patients with Deep Vein Thrombosis.
de Jong CMM; van den Hout WB; van Dijk CE; Heim N; van Dam LF; Dronkers CEA; Gautam G; Ghanima W; Gleditsch J; von Heijne A; Hofstee HMA; Hovens MMC; Huisman MV; Kolman S; Mairuhu ATA; van Mens TE; Nijkeuter M; van de Ree MA; van Rooden CJ; Westerbeek RE; Westerink J; Westerlund E; Kroft LJM; Klok FA
Thromb Haemost; 2024 Jun; 124(6):557-567. PubMed ID: 37984402
[TBL] [Abstract][Full Text] [Related]
15. The quality of oral anticoagulant therapy and recurrent venous thrombotic events in the Leiden Thrombophilia Study.
Gadisseur AP; Christiansen SC; VAN DER Meer FJ; Rosendaal FR
J Thromb Haemost; 2007 May; 5(5):931-6. PubMed ID: 17229054
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness and safety of early versus routine switching from low-molecular-weight heparin to maintenance therapy of rivaroxaban for acute iliofemoral vein thrombosis: a retrospective cohort study.
Hou W; Fang D; Yin S; Deng Y; Zhang J; Wang S; Liu L; Kong J; Huang M; Zhang X; Dai B; Feng X
Ann Vasc Surg; 2024 May; ():. PubMed ID: 38815910
[TBL] [Abstract][Full Text] [Related]
17. Natural history of arterial and venous thrombosis in children treated with low molecular weight heparin: a longitudinal study by ultrasound.
Revel-Vilk S; Sharathkumar A; Massicotte P; Marzinotto V; Daneman A; Dix D; Chan A
J Thromb Haemost; 2004 Jan; 2(1):42-6. PubMed ID: 14717964
[TBL] [Abstract][Full Text] [Related]
18. Safety of outpatient treatment in acute pulmonary embolism.
Erkens PM; Gandara E; Wells P; Shen AY; Bose G; Le Gal G; Rodger M; Prins MH; Carrier M
J Thromb Haemost; 2010 Nov; 8(11):2412-7. PubMed ID: 20735722
[TBL] [Abstract][Full Text] [Related]
19. Recanalization rate of proximal deep venous thrombosis related to therapeutic modality during six months follow-up.
Begić A; Begić E; Dilić M; Loga-Zec S; Babić N; Gojak R; Šljivo A
Med Glas (Zenica); 2022 Aug; 19(2):. PubMed ID: 35633124
[TBL] [Abstract][Full Text] [Related]
20. Large variation in anti-factor Xa levels with nadroparin as thromboprophylaxis in COVID-19 and non-COVID-19 critically ill patients.
de Maat MMR; van Leeuwen HJ; Roovers L; Ahlers SJGM; Lambers J; Hovens MMC
BMC Pharmacol Toxicol; 2024 Feb; 25(1):16. PubMed ID: 38321487
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
